UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Global Sequencing of Proteolytic Cleavage Sites in Apoptosis by Specific Labeling of Protein N Termini

Cell, 2008-09, Vol.134 (5), p.866-876

2008

Volltextzugriff (PDF)

The DegraBase: A Database of Proteolysis in Healthy and Apoptotic Human Cells

Molecular & cellular proteomics, 2013-03, Vol.12 (3), p.813-824

2013

Volltextzugriff (PDF)

Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non-Small Cell Lung Cancer Trials Using Real-World Data

Clinical cancer research, 2022-07, Vol.28 (13), p.2844-2853

2022

Volltextzugriff (PDF)

Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors

Clinical cancer research, 2017-05, Vol.23 (10), p.2423-2432

2017

Volltextzugriff (PDF)

Global kinetic analysis of proteolysis via quantitative targeted proteomics

Proceedings of the National Academy of Sciences - PNAS, 2012-02, Vol.109 (6), p.1913-1918

2012

Volltextzugriff (PDF)

Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors

Journal for immunotherapy of cancer, 2018-06, Vol.6 (1), p.61-12, Article 61

2018

Volltextzugriff (PDF)

Quantitative profiling of caspase-cleaved substrates reveals different drug-induced and cell-type patterns in apoptosis

Proceedings of the National Academy of Sciences - PNAS, 2012-07, Vol.109 (31), p.12432-12437

2012

Volltextzugriff (PDF)

Rapid and General Profiling of Protease Specificity by Using Combinatorial Fluorogenic Substrate Libraries

Proceedings of the National Academy of Sciences - PNAS, 2000-07, Vol.97 (14), p.7754-7759

2000

Volltextzugriff (PDF)

Prediction of protease substrates using sequence and structure features

Bioinformatics, 2010-07, Vol.26 (14), p.1714-1722

2010

Volltextzugriff (PDF)

Granzyme M Is a Regulatory Protease That Inactivates Proteinase Inhibitor 9, an Endogenous Inhibitor of Granzyme B

The Journal of biological chemistry, 2004-12, Vol.279 (52), p.54275-54282

2004

Volltextzugriff (PDF)

Cathepsin G Activates Protease-activated Receptor-4 in Human Platelets

The Journal of biological chemistry, 2000-03, Vol.275 (10), p.6819-6823

2000

Volltextzugriff (PDF)

Activation of Specific Apoptotic Caspases with an Engineered Small-Molecule-Activated Protease

Cell, 2010-08, Vol.142 (4), p.637-646

2010

Volltextzugriff (PDF)

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors

Clinical cancer research, 2019-06, Vol.25 (11), p.3220-3228

2019

Volltextzugriff (PDF)

Atezolizumab plus bevacizumab (A+B) in patients with unresectable hepatocellular carcinoma (uHCC): Real-world experience from a US community oncology network

Journal of clinical oncology, 2024-01, Vol.42 (3_suppl), p.447-447

2024

Volltextzugriff (PDF)

Abstract 29: Utility of novel clinico-genomic data to understand patient characteristics, treatments, and outcomes according to PIK3CA mutation status among hormone receptor-positive metastatic breast cancer patients

Clinical cancer research, 2020-06, Vol.26 (12_Supplement_1), p.29-29

2020

Volltextzugriff (PDF)

Overall survival of patients with metastatic castrate-resistant prostate cancer (mCRPC) who have PTEN tumor suppressor gene loss of function

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.58-58

2021

Volltextzugriff (PDF)

Altered Substrate Specificity of Drug-Resistant Human Immunodeficiency Virus Type 1 Protease

Journal of Virology, 2002-02, Vol.76 (3), p.1359-1368

2002

Volltextzugriff (PDF)

A validated surrogate analyte LC-MS/MS assay for quantitation of endogenous kynurenine and tryptophan in human plasma

Bioanalysis, 2018-08, Vol.10 (16), p.1307-1317

2018

Volltextzugriff (PDF)

Abstract 944: Development of predictive and pharmacodynamic biomarker strategies for GDC-0425, a checkpoint kinase 1 inhibitor, in combination with gemcitabine

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.944-944

2015

Volltextzugriff (PDF)

Selective Chemical Functional Probes of Granzymes A and B Reveal Granzyme B Is a Major Effector of Natural Killer Cell-Mediated Lysis of Target Cells

Chemistry & biology, 2005-05, Vol.12 (5), p.567-577

2005

Volltextzugriff (PDF)

A phase Ib dose escalation study of combined inhibition of IDO1 (GDC-0919) and PD-L1 (atezolizumab) in patients (pts) with locally advanced or metastatic solid tumors

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.105-105

2017

Volltextzugriff (PDF)

Isotope-Coded and Affinity-Tagged Cross-Linking (ICATXL): An Efficient Strategy to Probe Protein Interaction Surfaces

Journal of the American Chemical Society, 2006-08, Vol.128 (32), p.10362-10363

2006

Volltextzugriff (PDF)

Abstract CT139: Phase I study of GDC-0425, a checkpoint kinase 1 inhibitor, in combination with gemcitabine in patients with refractory solid tumors

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.CT139-CT139

2015

Volltextzugriff (PDF)

Tags for labeling protein N-termini with subtiligase for proteomics

Bioorganic & medicinal chemistry, 2008-11, Vol.18 (22), p.6000-6003

2008

Volltextzugriff (PDF)

1 – 25 von 34

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(33)
Dissertationen
(1)

Sprache

Englisch
(34)
Arabisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Global Sequencing of Proteolytic Cleavage Sites in Apoptosis by Specific Labeling of Protein N Termini

The DegraBase: A Database of Proteolysis in Healthy and Apoptotic Human Cells

Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non-Small Cell Lung Cancer Trials Using Real-World Data

Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors

Global kinetic analysis of proteolysis via quantitative targeted proteomics

Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors

Quantitative profiling of caspase-cleaved substrates reveals different drug-induced and cell-type patterns in apoptosis

Rapid and General Profiling of Protease Specificity by Using Combinatorial Fluorogenic Substrate Libraries

Prediction of protease substrates using sequence and structure features

Granzyme M Is a Regulatory Protease That Inactivates Proteinase Inhibitor 9, an Endogenous Inhibitor of Granzyme B

Cathepsin G Activates Protease-activated Receptor-4 in Human Platelets

Activation of Specific Apoptotic Caspases with an Engineered Small-Molecule-Activated Protease

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors

Atezolizumab plus bevacizumab (A+B) in patients with unresectable hepatocellular carcinoma (uHCC): Real-world experience from a US community oncology network

Abstract 29: Utility of novel clinico-genomic data to understand patient characteristics, treatments, and outcomes according to PIK3CA mutation status among hormone receptor-positive metastatic breast cancer patients

Overall survival of patients with metastatic castrate-resistant prostate cancer (mCRPC) who have PTEN tumor suppressor gene loss of function

Altered Substrate Specificity of Drug-Resistant Human Immunodeficiency Virus Type 1 Protease

A validated surrogate analyte LC-MS/MS assay for quantitation of endogenous kynurenine and tryptophan in human plasma

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Patients with Advanced Solid Tumors

Abstract 944: Development of predictive and pharmacodynamic biomarker strategies for GDC-0425, a checkpoint kinase 1 inhibitor, in combination with gemcitabine

Selective Chemical Functional Probes of Granzymes A and B Reveal Granzyme B Is a Major Effector of Natural Killer Cell-Mediated Lysis of Target Cells

A phase Ib dose escalation study of combined inhibition of IDO1 (GDC-0919) and PD-L1 (atezolizumab) in patients (pts) with locally advanced or metastatic solid tumors

Isotope-Coded and Affinity-Tagged Cross-Linking (ICATXL): An Efficient Strategy to Probe Protein Interaction Surfaces

Abstract CT139: Phase I study of GDC-0425, a checkpoint kinase 1 inhibitor, in combination with gemcitabine in patients with refractory solid tumors

Tags for labeling protein N-termini with subtiligase for proteomics

Suchergebnisse filtern